Wednesday, July 8, 2026

pharma · Atopic Dermatitis · Seborrheic Keratosis · ACRS

Aclaris Therapeutics

Aclaris Therapeutics patent portfolio — 18 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

170 N Radnor Chester Rd, Radnor Township, Pennsylvania, US HQ
2012 Founded
10 Employees
Public company Type
ACRS · NYSE Ticker
Company details
Status
Public
HQ
170 N Radnor Chester Rd, Radnor Township, Pennsylvania, US
Founded
2012
Employees
10
Programs
33
Drugs
12
Patents
18
Intelligence · Patents

Aclaris Therapeutics patents

18 pharmaceutical patents indexed for Aclaris Therapeutics. 0 expire within 24 months.

Aclaris Therapeutics has 18 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12403141

    Deuterated MK2 pathway inhibitors and methods of using the same

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12370195

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12297203

    Pyrrolopyrimidine ITK inhibitors

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12281111

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11844801

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11820775

    Pyrrolopyrimidine ITK inhibitors

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11739086

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10981906

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10800775

    Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 10729720

    Peroxide formulations and methods and applicators for using the same

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10653721

    Peroxide formulations and methods and applicators for using the same

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10493103

    Peroxide formulations and methods and applicators for using the same

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10335391

    Stabilized oxymetazoline formulations and their uses

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10316038

    Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10150783

    Heterocyclic ITK inhibitors for treating inflammation and cancer

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10098910

    Peroxide formulations and methods and applicators for using the same

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 9980983

    Peroxide formulations and methods and applicators for using the same

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 9675639

    Peroxide formulations and methods and applicators for using the same

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Aclaris Therapeutics have?

18 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Aclaris Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.